- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Iovance Biotherapeutics Inc (IOVA)
Iovance Biotherapeutics Inc stock price live, this page displays NASDAQ IOVA stock exchange data. View the IOVA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Iovance Biotherapeutics Inc real time stock price chart below.
What Is the Iovance Biotherapeutics Inc Stock Price Today?
The Iovance Biotherapeutics Inc stock price today is 3.83.
What Is the Stock Symbol for Iovance Biotherapeutics Inc?
The stock ticker symbol for Iovance Biotherapeutics Inc is IOVA.
Is IOVA the Same as $IOVA?
$IOVA is a common way to refer to the Iovance Biotherapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Iovance Biotherapeutics Inc Trade On?
Iovance Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Iovance Biotherapeutics Inc a Good Stock to Buy?
Determining whether Iovance Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Iovance Biotherapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IOVA quote. (ISIN: US4622601007)
What Is the Iovance Biotherapeutics Inc Stock Price Today?
The Iovance Biotherapeutics Inc stock price today is 3.83.
What Is the Stock Symbol for Iovance Biotherapeutics Inc?
The stock ticker symbol for Iovance Biotherapeutics Inc is IOVA.
Is IOVA the Same as $IOVA?
$IOVA is a common way to refer to the Iovance Biotherapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Iovance Biotherapeutics Inc Trade On?
Iovance Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Iovance Biotherapeutics Inc a Good Stock to Buy?
Determining whether Iovance Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Iovance Biotherapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IOVA quote. (ISIN: US4622601007)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.53
3.83
52 wk Range
1.64
5.63
IOVA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.533.83
52 wk Range
1.645.63
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IOVA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
9.00
Upside
+134.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics Inc SWOT Analysis
Market Positioning | Analyst consensus maintains a "Buy" recommendation with price targets ranging from $2 to $20, reflecting cautious optimism amid competitive pressures |
Pipeline Potential | Learn about Iovance's expanding clinical trials beyond melanoma, with potential catalysts in non-small cell lung cancer and other solid tumors |
Financial Hurdles | Delve into Iovance's financial challenges, including revenue misses and cash burn, balanced against cost-cutting measures extending the cash runway |
Amtagvi's Promise | Explore Iovance's flagship product Amtagvi, showing potential in advanced melanoma treatment with impressive response rates and long-term survival benefits |
Iovance Biotherapeutics Inc Earnings Call Summary for Q4/2025
- Q4 2025 revenue hit $87.1M, beating estimates by 5.71% with 30% QoQ growth; EPS of -$0.18 slightly missed forecast of -$0.17
- Stock surged 13.84% in pre-market to $3.29, later reaching $3.63 (26% gain) on strong revenue performance and improved fundamentals
- Gross margin improved to 50% from 43% in Q3; cost-saving initiatives extended cash runway into Q3 2027
- Amtagvi drove revenue growth; company targeting non-small cell lung cancer market, estimated 7x larger than melanoma segment
- Management projects continued expansion via treatment center growth, price increases, and international market entry pending regulatory approvals
Last Updated: 02/24/2026, 09:42 AM
Read Full TranscriptCompare IOVA to Peers and Sector
Metrics to compare | IOVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIOVAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −2.9x | −0.5x | |
PEG Ratio | −0.26 | −0.05 | 0.00 | |
Price / Book | 2.3x | 2.6x | 2.6x | |
Price / LTM Sales | 6.0x | 11.0x | 3.2x | |
Upside (Analyst Target) | 160.3% | 382.1% | 47.6% | |
Fair Value Upside | Unlock | 3.0% | 6.1% | Unlock |
Analyst Ratings
8 Buy
3 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 9.00
(+134.99% Upside)
Earnings
Latest Release
Feb 24, 2026
EPS / Forecast
-0.18 / -0.17
Revenue / Forecast
86.71M / 82.03M
People Also Watch
FAQ
What Is the Iovance Biotherapeutics (IOVA) Stock Price Today?
The Iovance Biotherapeutics stock price today is 3.83 USD.
What Stock Exchange Does Iovance Biotherapeutics Trade On?
Iovance Biotherapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Iovance Biotherapeutics?
The stock symbol for Iovance Biotherapeutics is "IOVA."
What Is the Iovance Biotherapeutics Market Cap?
As of today, Iovance Biotherapeutics market cap is 1.50B USD.
What Is Iovance Biotherapeutics's Earnings Per Share (TTM)?
The Iovance Biotherapeutics EPS (TTM) is -1.09.
When Is the Next Iovance Biotherapeutics Earnings Date?
Iovance Biotherapeutics will release its next earnings report on May 07, 2026.
From a Technical Analysis Perspective, Is IOVA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Iovance Biotherapeutics Stock Split?
Iovance Biotherapeutics has split 2 times.
How Many Employees Does Iovance Biotherapeutics Have?
Iovance Biotherapeutics has 975 employees.
What is the current trading status of Iovance Biotherapeutics (IOVA)?
As of Apr 15, 2026, Iovance Biotherapeutics (IOVA) is trading at a price of 3.83 USD, with a previous close of 3.64 USD. The stock has fluctuated within a day range of 3.53 USD to 3.83 USD, while its 52-week range spans from 1.64 USD to 5.63 USD.
What Is Iovance Biotherapeutics (IOVA) Price Target According to Analysts?
The average 12-month price target for Iovance Biotherapeutics is 9.00 USD, with a high estimate of 16 USD and a low estimate of 4 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +134.99% Upside potential.
What Is the IOVA Premarket Price?
IOVA's last pre-market stock price is 3.65 USD. The pre-market share volume is 101,590.00, and the stock has decreased by 0.01, or 0.27%.
What Is the IOVA After Hours Price?
IOVA's last after hours stock price is 3.85 USD, the stock has decreased by 0.03, or 0.79%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.